First, different from the other LP drivers such as ASCL1 and BRN2 which are significantly induced only in ARSI-treated tumor cells and thus function only in the resistant tumors, REV-ERBα expresses and plays very important roles in ARSI-sensitive adenocarcinomas by activating key tumorigenic programs including MAPK and PI3K-Akt signaling, cell cycle, and lipid metabolism (39). Here, AKT1 is linked to neoplasm.